तुलना करने के लिए मीट्रिक्स | IMM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −12.8x | −5.8x | −0.3x | |
PEG अनुपात | −0.33 | 0.07 | 0.00 | |
क़ीमत/बुक | 33.6x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 2.6x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 116.6% | 56.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.1% | 10.2% | अनलॉक करें |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.